AEON Biopharma (NASDAQ:AEON) Major Shareholder Timothy Lynch Buys 1,150,000 Shares of Stock

AEON Biopharma, Inc. (NASDAQ:AEON) major shareholder Timothy Lynch acquired 1,150,000 shares of the firm’s stock in a transaction on Wednesday, August 19th. The stock was purchased at an average price of $0.21 per share, with a total value of $241,500.00. Following the acquisition, the insider owned 6,500,000 shares of the company’s stock, valued at $1,365,000. This represents a 21.50% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Large shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.

AEON Biopharma Trading Down 0.5%

AEON Biopharma stock opened at $0.19 on Friday. The company has a market capitalization of $4.86 million, a price-to-earnings ratio of 1.07 and a beta of 0.65. The business’s fifty day simple moving average is $0.44 and its two-hundred day simple moving average is $0.78. AEON Biopharma, Inc. has a 12 month low of $0.18 and a 12 month high of $1.45.

Institutional Trading of AEON Biopharma

A hedge fund recently raised its stake in AEON Biopharma stock. Geode Capital Management LLC grew its stake in AEON Biopharma, Inc. (NASDAQ:AEON) by 27.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 60,134 shares of the company’s stock after buying an additional 13,061 shares during the quarter. Geode Capital Management LLC owned approximately 0.51% of AEON Biopharma worth $66,000 as of its most recent SEC filing. Institutional investors and hedge funds own 22.78% of the company’s stock.

Analyst Ratings Changes

Several research analysts have issued reports on the company. Lake Street Capital initiated coverage on AEON Biopharma in a research report on Thursday, July 30th. They issued a “buy” rating and a $1.00 target price on the stock. HC Wainwright reaffirmed a “buy” rating and set a $1.20 price target (down from $5.00) on shares of AEON Biopharma in a research report on Friday, August 14th. Finally, Zacks Research raised shares of AEON Biopharma to a “hold” rating in a report on Wednesday, May 27th. Three investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $1.10.

AEON Biopharma Company Profile

AEON Biopharma, Inc, formerly Allied Energy Corp., is a clinical‐stage biopharmaceutical company focused on developing and commercializing treatments for rare and orphan diseases. The company applies enzyme replacement and gene therapy platforms to address unmet medical needs in central nervous system and metabolic disorders. Its lead program, AES-103, is being developed as an enzyme replacement therapy for Crigler-Najjar syndrome, a hereditary condition characterized by high levels of unconjugated bilirubin.

Beyond AES-103, AEON Biopharma is advancing AES-201 for X-linked adrenoleukodystrophy (X-ALD), a progressive neurological disorder, and AES-104 for post–COVID-19 conditions, commonly referred to as “long COVID.” These programs are in preclinical or early clinical stages, with ongoing efforts to optimize delivery, evaluate safety profiles and establish proof of concept.